Literature DB >> 18450339

Participation in two phase II prophylactic HIV vaccine trials in the UK.

Kimberly Gray1, K Legg, A Sharp, N Mackie, F Olarinde, C De Souza, J Weber, B Peters.   

Abstract

There will be a continued imperative to recruit large numbers of healthy volunteers to early phase prophylactic HIV vaccine (PHV) trials. We studied mechanisms associated with participation in two related phase II PHV trials. The most cited reasons for volunteering were altruism and a personal connection to HIV. The most successful recruiting strategies targeted organisations dealing with HIV, health or social issues, or were directed to large audiences through the mass media. However, circulated emails and word of mouth were the most resource-effective approaches. Group discussions and the collection of a pool of potential volunteers were much less effective than one-to-one discussions and immediate screening after recruitment. We utilised our findings to devise key recommendations to assist PHV trial teams who are planning future studies.

Mesh:

Substances:

Year:  2008        PMID: 18450339     DOI: 10.1016/j.vaccine.2008.03.039

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Conceptual framework for behavioral and social science in HIV vaccine clinical research.

Authors:  Chuen-Yen Lau; Edith M Swann; Sagri Singh; Zuhayr Kafaar; Helen I Meissner; James P Stansbury
Journal:  Vaccine       Date:  2011-08-05       Impact factor: 3.641

2.  Typologies of Altruistic and Financial Motivations for Research Participation.

Authors:  Lisa J Chin; Jacqueline A Berenson; Robert L Klitzman
Journal:  J Empir Res Hum Res Ethics       Date:  2016-10       Impact factor: 1.742

3.  Exceptional Risk: Healthy Volunteers' Perceptions of HIV/AIDS Clinical Trials.

Authors:  Marci D Cottingham; Julianne M Kalbaugh; Teresa Swezey; Jill A Fisher
Journal:  J Acquir Immune Defic Syndr       Date:  2018-10-01       Impact factor: 3.731

4.  Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.

Authors:  Laura Richert; Adélaïde Doussau; Jean-Daniel Lelièvre; Vincent Arnold; Véronique Rieux; Amel Bouakane; Yves Lévy; Geneviève Chêne; Rodolphe Thiébaut
Journal:  Trials       Date:  2014-02-26       Impact factor: 2.279

5.  Experiences on recruitment and retention of volunteers in the first HIV vaccine trial in Dar es Salam, Tanzania - the phase I/II HIVIS 03 trial.

Authors:  Muhammad Bakari; Patricia Munseri; Joel Francis; Eric Aris; Candida Moshiro; David Siyame; Mohamed Janabi; Mary Ngatoluwa; Said Aboud; Eligius Lyamuya; Eric Sandström; Fred Mhalu
Journal:  BMC Public Health       Date:  2013-12-09       Impact factor: 3.295

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.